Deciphera Patent-Cliff Exposure & CMS Drug Spending Portfolio

Deciphera (US): 2 reconciled FDA prescription therapies, $89.2M 2024 CMS Part D & Medicaid spend, and 7 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2042-01-01
2024 CMS Total Public Spend$89.2M
2024 Medicare Part D Spend$78.7M
2024 Medicaid Spend$10.6M
California HCAI SB 17 Filings7 WAC filings (max 25.1% 2-yr change)